A Phase 2 interventional study of Eltrombopag and Rabbit ATG in Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 16th largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 2, and was the 7th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is the only one that started in 2015, is one of 7 in phase 2, and was the 5th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy. The objective was to assess additive effects of eltorombopag on overall response rate (ORR) at 6 months (Week 26) of treatment with ATG/CsA. Subjects were assessed at least weekly for safety during the period from the start of ATG/CsA to 4 weeks after the start of administration of eltrombopag. After that, subjects had visits every 2 weeks until Week 26. Subjects in whom the treatment was assessed as effective at Week 26 could continued treatment with eltrombopag after 6 months when clinically indicated at the discretion of the investigator. There were five follow-up visits: at discontinuation of the treatment of eltrombopag, and Weeks 1, 2, 3, 4 and 26 after treatment discontinuation. As this study was the first Japanese phase II study in which this product was administered in combination with ATG/CsA to subjects with naive moderate or more severe AA, the subject number of this study was determined to be 10 based on the feasibility survey.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
Drug: Eltrombopag · Drug: Rabbit ATG · Drug: CsA
Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
ORR at 6 Months: Overall Response Rate (ORR) Defined as the Number of Participants Who Met the Criteria of Either Complete Response (CR) or Partial Response (PR) at Week 26
ORR will be calculated after 6 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence. ORR includes Complete Response (CR) and Partial Response (PR) Rate.
Time frame: Week 26
ORR at 3 Months
ORR will be calculated after 3 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence.
Time frame: Week 14
Complete Response (CR), and Partial Response (PR) Rate at 3 Months
CR and PR will be calculated after 3 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence.
Time frame: Week 14
CR Rate Based on the Criteria Used in NIH 12-H-0150 Study at 6 Months
CR criteria used in NIH 12-H-150 study is as follows: Hemoglobin \>10 gram (g)/ deciliter (dL), and Absolute neutrophil count (ANC) \>1,000/microliter, and Platelets \>100,000/microliter.
Time frame: Week 26
Changes in Hematology Parameters (Haemoglobin) in the Absence of Platelet Transfusion
The change in hematology values ( haemoglobin) were evaluated.
Time frame: Week 26 and week 104
Changes in Hematology Parameters in the Absence of Platelet Transfusion
The change in hematology values from baseline for platelets, neutrophils and reticulocytes were evaluated.
Time frame: Week 26 and week 104
Frequency of Platelet and Red Blood Cells (RBC) Transfusions
RBC transfusion dependency defined as at least one RBC transfusion within 8 weeks prior to D1. Platelet or RBC transfusions will be based on physician's subjective judgement. Platelet transfusion will be done if the platelet count is less than 10×10\^9/liter (L) with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
Time frame: Baseline, Week 26
Volume of Platelet and RBC Transfusions
Platelet or RBC transfusions will be based on physician's subjective judgement. Platelet transfusion will be done if the platelet count is less than 10×10\^9/L with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
Time frame: Baseline, Week 26
The Proportion of Subjects Whose Transfusion Unit (or Volume) Are Decreased or Who Became Transfusion (Platelet, RBC) Independent
The proportions of the subjects for whom the amount of blood transfusion (platelets and RBC) decreased or the proportions of the subjects for whom blood transfusion (platelets and RBC) became unnecessary. Platelet transfusion will be done if the platelet count is less than 10×10\^9/L with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
Time frame: Week 26
Duration of Hospitalization
Duration of hospitalization is the time period from the administration of ATG up to discharge.
Time frame: Week 26
Time to Onset of CR and PR
The time to onset of CR and PR will be determined by measuring platelet, reticulocyte, neutrophil and transfusion independence.
Time frame: Week 26
Duration of CR or PR
Duration for CR or PR will be determined by measuring platelet, reticulocyte, neutrophil and transfusion independence.
Time frame: Week 104
Degree of Exposure to Eltrombopag : Average Daily Dose
Time frame: Week 104
Degree of Exposure to Eltrombopag : Cumulative Dose
The cumulative dose of drug administered to the subject will be calculated.
Time frame: Week 104
Degree of Exposure to Eltrombopag : Days on Study
Time frame: Week 104
Number of Participants With Adverse Events
Adverse events will be collected from the start of study treatment until the approval.
Time frame: though study completion , approximately 2 years
Vital Signs (Blood Pressure) as a Measure of Safety and Tolerability
Vital sign measurements : blood pressure
Time frame: baseline and Week 26
12-lead Electrocardiogram (ECG) as Measure of Safety and Tolerability
Triplicate 12-lead ECGs will be obtained at designated time points during the study using an ECG machine that calculates the heart rate and measures PR, QRS, QT, and QT interval corrected by Fridericia formula (QTcF) intervals.
Time frame: Baseline, Week 26
The Trough Concentrations of Eltrombopag Following Repeat Doses of at 75 mg, 50 mg and 25 mg
Blood samples will be collected after repeat (14 days) doses of eltrombopag 75, 50, 25 mg to determine the plasma eltrombopag concentration prior to the next dose.
Time frame: day 15
The Concentration After 4 Hours of Dose of Eltrombopag 75 mg
Blood sample will be collected at 4 hours after repeat (14 days) dose of eltrombopag 75 mg
Time frame: day 15
Composite of Laboratory Parameters Assessment as a Safety Measure (Haemoglobin and Albumin).
The laboratory test values (haemoglobin and albumin) were calculated at each time point of evaluation.
Time frame: Baseline, Week 26
Composite of Laboratory Parameters Assessment as a Safety Measure (Lymphocytes and Neutrophils).
The laboratory test values (lymphocytes and neutrophils) were calculated at each time point of evaluation.
Time frame: Baseline, Week 26
Composite of Laboratory Parameters Assessment as a Safety Measure (Alcaline Phosphatase and Aspartate Amino Transferase) .
The laboratory test values (Alcaline Phosphatase and Aspartate Amino Transferase) were calculated at each time point of evaluation.
Time frame: Baseline, Week 26
Composite of Laboratory Parameters Assessment as a Safety Measure.
The laboratory test values (hematological /biochemical examinations) were calculated at each time point of evaluation.
Time frame: Baseline, Week 26
Vital Signs (Temperature) as a Measure of Safety and Tolerability
Vital sign measurements : temperature
Time frame: baseline and Week 26
Vital Signs (Pulse Rate) as a Measure of Safety and Tolerability
Vital sign measurements : pulse rate.
Time frame: baseline and Week 26
10 subject started eltrombopag, and 1 subject was withdrawn from the study before starting eltrombopag, as he did not meet the eligibility criteria prior to receiving eltrombopag.
| Milestone | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Started | 10 |
| Completed | 6 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 3 |
ORR will be calculated after 6 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence. ORR includes Complete Response (CR) and Partial Response (PR) Rate.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| CR+PR | 7 |
| CR | 0 |
| PR | 7 |
ORR will be calculated after 3 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| ORR at 3 Months | 2 |
CR and PR will be calculated after 3 months of eltrombopag administration by measuring platelet, reticulocyte, neutrophil and transfusion independence.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| CR | 0 |
| PR | 2 |
CR criteria used in NIH 12-H-150 study is as follows: Hemoglobin \>10 gram (g)/ deciliter (dL), and Absolute neutrophil count (ANC) \>1,000/microliter, and Platelets \>100,000/microliter.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| CR Rate Based on the Criteria Used in NIH 12-H-0150 Study at 6 Months | 1 |
The change in hematology values ( haemoglobin) were evaluated.
| g/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Haemoglobin changes from baseline, week 26 (g/L) | 24.6 ± 19.20 |
| Haemoglobin changes from baseline, week 104 (g/L) | 39.0 ± 3.61 |
The change in hematology values from baseline for platelets, neutrophils and reticulocytes were evaluated.
| Gi/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| neutrophils changes from baseline, week 26 (Gi/L) | 1.2196 ± 0.59501 |
| neutrophils changes from baseline, week 104 (Gi/L) | 1.2978 ± 0.65819 |
| platelets changes from baseline, week 26 (Gi/L) | 66.94 ± 57.187 |
| platelets changes from baseline, week 104 (Gi/L) | 107.33 ± 4.041 |
| reticulocytes changes from baseline week 26 (Gi/L) | 30.0175 ± 21.81519 |
| reticulocytes changes from baseline week104 (Gi/L) | 48.0900 ± 29.96719 |
RBC transfusion dependency defined as at least one RBC transfusion within 8 weeks prior to D1. Platelet or RBC transfusions will be based on physician's subjective judgement. Platelet transfusion will be done if the platelet count is less than 10×10\^9/liter (L) with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
| mean of transfusions number | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Baseline RBC transfusions | 4.0 ± 3.10 |
| Week 26 RBC transfusions | 1.0 ± 2.24 |
| Baseline Platelet transfusion | 3.4 ± 2.77 |
| Week 26 Platelet transfusion | 1.0 ± 1.91 |
Platelet or RBC transfusions will be based on physician's subjective judgement. Platelet transfusion will be done if the platelet count is less than 10×10\^9/L with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
| mL | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Baseline RBC transfusion | 1600.0 ± 1239.35 |
| Week 26 RBC transfusion | 400.0 ± 894.43 |
| Baseline Platelet transfusion | 687.5 ± 559.18 |
| Week 26 Platelet transfusion | 200.0 ± 382.97 |
The proportions of the subjects for whom the amount of blood transfusion (platelets and RBC) decreased or the proportions of the subjects for whom blood transfusion (platelets and RBC) became unnecessary. Platelet transfusion will be done if the platelet count is less than 10×10\^9/L with significant bleeding tendency or the platelet count is less than 20×10\^9/L with pyrexia. RBC transfusion will be done to keep the hemoglobin concentration at over 7 g/dL or in the presence of clinical symptoms such as dyspnea.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Baseline RBC transfusion dependence | 6 |
| RBC Transfusion decrease or free | 4 |
| Baseline Platelet transfusion dependence | 8 |
| Platelet Transfusion decrease or free | 5 |
Duration of hospitalization is the time period from the administration of ATG up to discharge.
| days | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Duration of Hospitalization | 49.0 (13 to 123) |
The time to onset of CR and PR will be determined by measuring platelet, reticulocyte, neutrophil and transfusion independence.
| months | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Time to Onset of CR and PR | 3.75 (2.5 to 4.8) |
Duration for CR or PR will be determined by measuring platelet, reticulocyte, neutrophil and transfusion independence.
| months | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Duration of CR or PR | 17.28 (6.0 to 20.3) |
| mg/day | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Degree of Exposure to Eltrombopag : Average Daily Dose | 43.8 ± 23.19 |
The cumulative dose of drug administered to the subject will be calculated.
| mg | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Degree of Exposure to Eltrombopag : Cumulative Dose | 17687.5 ± 7179.77 |
| days | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Degree of Exposure to Eltrombopag : Days on Study | 493.7 ± 233.69 |
Adverse events will be collected from the start of study treatment until the approval.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| number of participants with an AE | 10 |
| with an AE related to any study treatment | 8 |
| with an AE related to Eltrombopag | 5 |
| with an AE related to CsA | 8 |
| number of participants with a SAE | 2 |
Vital sign measurements : blood pressure
| mmHg | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| baseline systolic blood pressure (mmHg) | 115.7 ± 15.06 |
| week 26 systolic blood pressure (mmHg) | 126.4 ± 17.12 |
| baseline diastolic blood pressure (mmHg) | 64.3 ± 11.78 |
| week 26 diastolic blood pressure (mmHg) | 76.9 ± 13.11 |
Triplicate 12-lead ECGs will be obtained at designated time points during the study using an ECG machine that calculates the heart rate and measures PR, QRS, QT, and QT interval corrected by Fridericia formula (QTcF) intervals.
| Participants | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| screening (baseline) — normal | 8 |
| screening (baseline) — abnormal not clinically significant | 2 |
| screening (baseline) — abnormal clinically significant | 0 |
| week 26 — normal | 6 |
| week 26 — abnormal not clinically significant | 3 |
| week 26 — abnormal clinically significant | 0 |
Blood samples will be collected after repeat (14 days) doses of eltrombopag 75, 50, 25 mg to determine the plasma eltrombopag concentration prior to the next dose.
| ng/mL | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Eltrombopag 25 mg day 15, 0h (predose) | 6070 ± NA |
| Eltrombopag 50 mg day 15, 0h (predose) | 20800 ± 7920 |
| Eltrombopag 75 mg day 15, 0h (predose) | 21800 ± 7370 |
Blood sample will be collected at 4 hours after repeat (14 days) dose of eltrombopag 75 mg
| ng/mL | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| day 15, 0 hour (predose) | 21800 ± 7370 |
| day 15, 4 hours (post dose) | 28400 ± 8960 |
The laboratory test values (haemoglobin and albumin) were calculated at each time point of evaluation.
| g/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| hemoglobin baseline (g/L) | 77.2 ± 4.52 |
| hemoglobin week 26 (g/L) | 102.4 ± 17.64 |
| Albumin baseline (g/L) | 38.7 ± 4.83 |
| Albumin Week 26 (g/L) | 44.9 ± 2.52 |
The laboratory test values (lymphocytes and neutrophils) were calculated at each time point of evaluation.
| Gi/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| White blood cell count baseline (Gi/L) | 1.896 ± 0.9200 |
| White blood cell count week 26(Gi/L) | 2.682 ± 0.8347 |
| lymphocytes baseline (Gi/L) | 1.3943 ± 0.60771 |
| lymphocytes week 26 (Gi/L) | 0.7108 ± 0.34079 |
| Total Neutrophils Baseline (Gi/L) | 0.4033 ± 0.38230 |
| Total Neutrophils Week 26 (Gi/L) | 1.6120 ± 0.468 |
The laboratory test values (Alcaline Phosphatase and Aspartate Amino Transferase) were calculated at each time point of evaluation.
| IU/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Alcaline phosphatase baseline (IU/L) | 186.7 ± 57.03 |
| Alcaline phosphatase Week 26 (IU/L) | 319.6 ± 114.58 |
| Alanine Amino Transferase baseline (IU/L) | 14.3 ± 3.71 |
| Alanine Amino Transferase Week 26(IU/L) | 16.8 ± 7.48 |
| Aspartate Amino Transferase baseline (IU/L) | 14.9 ± 2.47 |
| Aspartate Amino Transferase Week 26(IU/L) | 18.8 ± 4.66 |
The laboratory test values (hematological /biochemical examinations) were calculated at each time point of evaluation.
| umol/L | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Direct Bilirubin baseline (umol/L) | 2.565 ± 0.9012 |
| Direct Bilirubin week 26 (umol/L) | 2.850 ± 1.2092 |
| Indirect Bilirubin baseline (umol/L) | 5.301 ± 2.2002 |
| Indirect Bilirubin week 26 (umol/L) | 6.080 ± 1.7336 |
| Total Bilirubin baseline (umol/L) | 7.866 ± 2.9287 |
| Total Bilirubin week 26 (umol/L) | 8.930 ± 2.5331 |
| Creatinine baseline (umol/L) | 59.6700 ± 11.86193 |
| Creatinine week 26 (umol/L) | 79.9529 ± 23.55122 |
| Potassium baseline (umol/L) | 3.88 ± 0.371 |
| Potassium week 26 (umol/L) | 4.27 ± 0.335 |
| Sodium baseline (umol/L) | 140.7 ± 1.42 |
| Sodium week 26 (umol/L) | 140.4 ± 1.74 |
Vital sign measurements : temperature
| °C | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| baseline temperature (°C) | 36.55 ± 0.448 |
| week 26 temperature (°C) | 36.71 ± 0.379 |
Vital sign measurements : pulse rate.
| beats/min | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| baseline heart rate (beats /min) | 76.2 ± 10.38 |
| week 26 heart rate (beats/min) | 80.4 ± 10.82 |
Collected over Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit up to approximately 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag+ATG/CsA | 0/10 (0%) | 2/10 (20%) | 10/10 (100%) |
| Event | Eltrombopag+ATG/CsA |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/10 |
| NephrolithiasisRenal and urinary disorders | 1/10 |
| Event | Eltrombopag+ATG/CsA |
|---|---|
| NauseaGastrointestinal disorders | 6/10 |
| HeadacheNervous system disorders | 5/10 |
| ConstipationGastrointestinal disorders | 4/10 |
| VomitingGastrointestinal disorders | 4/10 |
| OedemaGeneral disorders | 4/10 |
| PyrexiaGeneral disorders | 4/10 |
| Renal impairmentRenal and urinary disorders | 4/10 |
| HypertensionVascular disorders | 4/10 |
| StomatitisGastrointestinal disorders | 3/10 |
| NasopharyngitisInfections and infestations | 3/10 |
| Age, Continuous(years) | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Median | 55.5 (39 to 67) |
| Sex: Female, Male(Participants) | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Female | 7 |
| Male | 3 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag+Rabbit ATG/CsA Arm |
|---|---|
| Asian Japanese | 10 |
Ran from May 2015 to primary completion in Jul 2016, 13 months.
Results were first posted in Jul 2019, 3 years after primary completion.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eltrombopag · Cyclosporine